Manfred Hauben

4.3k total citations
77 papers, 2.4k citations indexed

About

Manfred Hauben is a scholar working on Toxicology, Pharmacology and Computational Theory and Mathematics. According to data from OpenAlex, Manfred Hauben has authored 77 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Toxicology, 24 papers in Pharmacology and 22 papers in Computational Theory and Mathematics. Recurrent topics in Manfred Hauben's work include Pharmacovigilance and Adverse Drug Reactions (61 papers), Drug-Induced Adverse Reactions (24 papers) and Computational Drug Discovery Methods (22 papers). Manfred Hauben is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (61 papers), Drug-Induced Adverse Reactions (24 papers) and Computational Drug Discovery Methods (22 papers). Manfred Hauben collaborates with scholars based in United States, United Kingdom and Germany. Manfred Hauben's co-authors include Jeffrey K Aronson, Lester Reich, Andrew Bate, Charles M. Gerrits, Xiaofeng Zhou, Eric Hung, Louisa Walsh, David Madigan, Wendy P. Stephenson and Eugène van Puijenbroek and has published in prestigious journals such as Blood, Bioinformatics and Annals of the Rheumatic Diseases.

In The Last Decade

Manfred Hauben

76 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Manfred Hauben United States 26 1.4k 548 448 297 270 77 2.4k
Roland Orre Sweden 9 1.7k 1.2× 609 1.1× 555 1.2× 373 1.3× 231 0.9× 15 2.5k
G. Niklas Norén Sweden 26 1.4k 1.0× 580 1.1× 418 0.9× 375 1.3× 355 1.3× 63 2.9k
Sten Olsson Sweden 20 1.6k 1.1× 348 0.6× 473 1.1× 165 0.6× 529 2.0× 47 2.5k
Bernard Bégaud France 30 1.4k 1.0× 305 0.6× 726 1.6× 233 0.8× 344 1.3× 79 3.0k
Ronald H.B. Meyboom Netherlands 25 900 0.7× 274 0.5× 455 1.0× 122 0.4× 208 0.8× 46 2.2k
Françoise Haramburu France 30 1.5k 1.1× 274 0.5× 605 1.4× 193 0.6× 311 1.2× 129 2.7k
Hubert G.M. Leufkens Netherlands 23 879 0.6× 243 0.4× 400 0.9× 198 0.7× 480 1.8× 62 3.0k
Marie Lindquist Sweden 24 2.5k 1.8× 840 1.5× 860 1.9× 458 1.5× 449 1.7× 45 3.9k
Preciosa M. Coloma Netherlands 25 673 0.5× 208 0.4× 227 0.5× 213 0.7× 247 0.9× 46 1.9k
Ghada Miremont‐Salamé France 22 801 0.6× 207 0.4× 331 0.7× 125 0.4× 182 0.7× 76 1.8k

Countries citing papers authored by Manfred Hauben

Since Specialization
Citations

This map shows the geographic impact of Manfred Hauben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manfred Hauben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manfred Hauben more than expected).

Fields of papers citing papers by Manfred Hauben

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manfred Hauben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manfred Hauben. The network helps show where Manfred Hauben may publish in the future.

Co-authorship network of co-authors of Manfred Hauben

This figure shows the co-authorship network connecting the top 25 collaborators of Manfred Hauben. A scholar is included among the top collaborators of Manfred Hauben based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manfred Hauben. Manfred Hauben is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hauben, Manfred, et al.. (2025). How LLMs can advance safety case intake—points to consider and insights from a proof of concept. Therapeutic Advances in Drug Safety. 16. 1601838446–1601838446.
2.
Hauben, Manfred, et al.. (2024). Knowledge Graphs in Pharmacovigilance: A Step-By-Step Guide. Clinical Therapeutics. 46(7). 538–543. 2 indexed citations
3.
Hauben, Manfred, et al.. (2024). Current Approaches in Postapproval Vaccine Safety Studies Using Real-World Data: A Systematic Review of Published Literature. Clinical Therapeutics. 46(7). 555–564. 2 indexed citations
4.
Marrero, Osvaldo, Eric Hung, & Manfred Hauben. (2016). Seasonal and Geographic Variation in Adverse Event Reporting. Drugs - Real World Outcomes. 3(3). 297–306. 14 indexed citations
5.
Hauben, Manfred & Eric Hung. (2013). A Quantitative Analysis of the Spontaneous Reporting of Congestive Heart Failure‐Related Adverse Events With Systemic Anti‐Fungal Drugs. The Journal of Clinical Pharmacology. 53(7). 762–772. 9 indexed citations
6.
7.
Shibata, Atsuko & Manfred Hauben. (2011). Pharmacovigilance, signal detection and signal intelligence overview. International Conference on Information Fusion. 1–7. 19 indexed citations
8.
Wang, Hsin‐Wei, Alan M. Hochberg, Ronald K. Pearson, & Manfred Hauben. (2010). An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database. Drug Safety. 33(12). 1117–1133. 56 indexed citations
9.
Pearson, Ronald K., Manfred Hauben, David I Goldsmith, et al.. (2009). Influence of the MedDRA® hierarchy on pharmacovigilance data mining results. International Journal of Medical Informatics. 78(12). e97–e103. 54 indexed citations
10.
Hochberg, Alan M., Manfred Hauben, Ronald K. Pearson, et al.. (2009). An Evaluation of Three Signal-Detection Algorithms Using a Highly Inclusive Reference Event Database. Drug Safety. 32(6). 509–525. 35 indexed citations
11.
Hochberg, Alan M., Manfred Hauben, Ronald K. Pearson, Donald J. O’Hara, & Stephanie J. Reisinger. (2009). Systematic Investigation of Time Windows for Adverse Event Data Mining for Recently Approved Drugs. The Journal of Clinical Pharmacology. 49(6). 626–633. 8 indexed citations
12.
Hauben, Manfred & Jeffrey K Aronson. (2007). Gold Standards in Pharmacovigilance. Drug Safety. 30(8). 645–655. 47 indexed citations
13.
Hauben, Manfred, Lester Reich, Charles M. Gerrits, & David Madigan. (2007). Detection of Spironolactone-Associated Hyperkalaemia Following the Randomized Aldactone Evaluation Study (RALES). Drug Safety. 30(12). 1143–1149. 16 indexed citations
14.
Aronson, Jeffrey K & Manfred Hauben. (2006). Anecdotes that provide definitive evidence. BMJ. 333(7581). 1267–1269. 78 indexed citations
15.
Hauben, Manfred, Lester Reich, & Charles M. Gerrits. (2006). Reports of hyperkalemia after publication of RALES—a pharmacovigilance study. Pharmacoepidemiology and Drug Safety. 15(11). 775–783. 15 indexed citations
16.
Hauben, Manfred, David Madigan, Charles M. Gerrits, Louisa Walsh, & Eugène van Puijenbroek. (2005). The role of data mining in pharmacovigilance. Expert Opinion on Drug Safety. 4(5). 929–948. 190 indexed citations
17.
Almenoff, June S., Joseph M. Tonning, A. Lawrence Gould, et al.. (2005). Perspectives on the Use of Data Mining in Pharmacovigilance. Drug Safety. 28(11). 981–1007. 173 indexed citations
18.
Hauben, Manfred & Lester Reich. (2005). Potential Utility of Data‐Mining Algorithms for Early Detection of Potentially Fatal/Disabling Adverse Drug Reactions: A Retrospective Evaluation. The Journal of Clinical Pharmacology. 45(4). 378–384. 29 indexed citations
19.
Hauben, Manfred & Xiaofeng Zhou. (2003). Quantitative Methods in Pharmacovigilance. Drug Safety. 26(3). 159–186. 136 indexed citations
20.
Hauben, Manfred & Guy W. Amsden. (2002). The Association of Erythromycin and Infantile Hypertrophic Pyloric Stenosis. Drug Safety. 25(13). 929–942. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roland Orre Breakdown of academic impact, for papers by G. Niklas Norén Breakdown of academic impact, for papers by Sten Olsson Breakdown of academic impact, for papers by Bernard Bégaud Breakdown of academic impact, for papers by Ronald H.B. Meyboom Breakdown of academic impact, for papers by Françoise Haramburu Breakdown of academic impact, for papers by Hubert G.M. Leufkens Breakdown of academic impact, for papers by Marie Lindquist Breakdown of academic impact, for papers by Preciosa M. Coloma Breakdown of academic impact, for papers by Ghada Miremont‐Salamé
Rankless by CCL
2026